Celldex's Barzolvolimab Shows Profound, Durable Quality of Life Improvements in Phase 2 Urticaria Studies
CLDX has more than doubled off its 52-week low of $14.4 on light trading volume (0.1× avg).
Summary
Celldex Therapeutics presented highly positive Phase 2 data for its investigational drug barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) at AAD 2026. The data highlighted rapid, profound, and durable improvements in patient quality of life (QoL) across all measured domains, with 94% of well-controlled CSU patients achieving a DLQI of 0/1 at Week 52. Crucially, the analysis indicated sustained off-treatment QoL improvements and suggested potential disease modification, reinforcing barzolvolimab's profile as a best-in-class treatment. This strong QoL data significantly de-risks the ongoing Phase 3 trials for CSU and CIU, as previously noted in the company's 10-K, and strengthens the drug's commercial potential by demonstrating a clear patient benefit beyond symptom control. Investors will watch for further updates from the ongoing Phase 3 trials.
At the time of this announcement, CLDX was trading at $30.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $14.40 to $34.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.